Industry associations still resisting non-disclosure agreements for negotiation

A unique three‑way collaboration announced in Sydney seeks to build a practical blueprint for how Australia can confront a growing dementia crisis, with a particular focus on Alzheimer’s disease.

Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients.

It will terrify some to imagine an even larger HTA industrial complex. Yet AI has the potential to fundamentally change its character and make it far more affordable and accessible for more organisations and people. It can open up an institutional framework that is about as accessible as an exclusive golf club.

CSL has announced it will begin clinical trials to evaluate the safety and efficacy of immunoglobulin produced with its next-generation Horizon 2 manufacturing process.

AusBiotech has launched a new membership category in its 40th year, AusBiotech Connect, designed specifically for companies in their first two years of operation.

Professor Trent Munro, General Manager of the BRIJ, and Rebekah Cassidy, CEO of AusBiotech, spoke with BioPharmaDispatch-BPDInsights about the precinct’s contribution to how Australia’s life sciences sector is moving from scientific promise to commercial impact.

“Since AbbVie’s inception 13 years ago, we have been rewarded a Great Place to Work - a truly remarkable achievement. This is not by accident, and it is not an easy feat. It takes considered effort and real intentionality," said Nat McNeil, Vice President and General Manager, AbbVie Australia and New Zealand.

In an investor presentation in Auckland, the company said its portfolio now includes eight patented projects, 24 off-patent injectables, and several early-stage commercialisation efforts.

The new IQVIA report found that nearly 200 orphan drug designations were granted between 2018 and 2025, with most progressing to regulatory approval but far fewer gaining reimbursement.

A new global survey, including Australia, has painted a stark picture of how COVID-19 continues to shape daily life for many medically vulnerable people.

Professor Jo Douglass, specialist physician and Professor of Medicine at the University of Melbourne, called the approval of another treatment option a positive development for patients who face ongoing, sometimes life‑threatening breathing difficulties.

Chronic Pain Australia’s '2026 National Pain Report: Pain Lives Here', released during National Pain Week, is calling for action on the disconnect between the widespread impact of chronic pain and the lack of recognition, measurement and action.

Boehringer Ingelheim has partnered with patient groups to launch 'Patient Input Buddy', an AI platform designed to make it easier for people to provide input into Pharmaceutical Benefits Advisory Committee evaluations.

ACT, the party led by New Zealand's Deputy Prime Minister David Seymour, has announced an historic pre-election commitment to reversing three decades of chronic under-funding for Pharmac.

What makes ACT's commitment to reverse the 30-year decline in New Zealand's medicines spend so remarkable is its clear demonstration of intent. Compare that to the current state of medicines policy in Australia.

The 2026 PCPA Cancer Summit will bring together leading cancer specialists, policymakers, patient advocates and industry partners in Melbourne on 28 and 29 August to explore solutions to improving access to treatment.

The organisation said the appointment brings expertise in AI governance and privacy to its board, adding depth at a time of unprecedented technological change. 

Misleading claims about patient groups and the industry, combined with an irrational hyperventilation about a rational response to new global realities, have made for an interesting week. The price reduction mantra and whether it can be moderated?

The finalist list for the 2026 Patients Australia awards has revealed a wide range of organisations and professionals whose work is shaping patient care and medical research.